Top Pharma Stocks to invest in India under Rs 200
India is the pharmacy of the world, supplying over 20% of global generic medicines and exporting to 200+ countries. The Union Budget 2026–27 launched the Biopharma SHAKTI programme with ₹10,000 crore over 5 years to build a comprehensive biopharma ecosystem, signalling strong government support for the sector.
For investors who want pharma exposure without paying premium prices for Sun Pharma (₹1,700+) or Divi's Labs (₹6,000+), there are quality pharmaceutical stocks available under ₹200 per share.
Why Invest in Pharma Stocks Under ₹200?
- Low entry price: Enables portfolio diversification with limited capital
- High growth potential: Smaller/mid-cap pharma companies can grow faster than large-caps
- Essential sector: Medicines are never out of demand regardless of economic cycles
- Government support: PLI schemes, Biopharma SHAKTI, export incentives benefiting smaller players
- USFDA approvals: Even a single US drug approval can dramatically re-rate a small pharma stock
- Post-COVID resilience: Healthcare awareness permanently elevated demand for OTC products and diagnostics
Understanding Pharma Sub-Sectors
Top Pharma Stocks Under ₹200 in India 2026
1. Sun Pharma Advanced Research Company (SPARC)
SPARC is the R&D arm of Sun Pharmaceutical Industries, focusing on innovative drug delivery systems and novel formulations. While Sun Pharma itself trades above ₹1,700, SPARC is a separate listed entity that captures the innovation engine at a far lower price.
Key Highlights:
- Therapeutic focus: Oncology, neurology, dermatology
- Pipeline of novel drug delivery innovations
- Backed by Sun Pharma's research infrastructure and parentage
- Long-term play on breakthrough pharmaceutical IP
Investment Case: SPARC is an R&D company revenue may be low, but it holds a pipeline of future drugs. High risk, high reward. Suitable only for investors who understand the pharma innovation cycle.
2. Morepen Laboratories Ltd
Morepen is a diversified healthcare company producing APIs, formulations, diagnostics, and OTC health products. Its recognisable consumer brands (Dr. Morepen thermometers, BP monitors, glucometers) give it a retail healthcare presence alongside its B2B pharmaceutical business.
Key Highlights:
- Revenue from APIs, OTC devices, formulations
- Consumer health brand recognition Dr. Morepen
- Beneficiary of domestic healthcare awareness trends
- Diversified revenue across B2B and B2C
Investment Case: Morepen's diversification across APIs, consumer devices, and OTC products reduces single-segment risk. Post-COVID diagnostics demand provides growth tailwind.
3. SeQuent Scientific Ltd - Animal Health Specialist
SeQuent is a global animal health company producing veterinary APIs and formulations. With India's growing livestock sector and rising global demand for veterinary medicines, SeQuent is a niche but high-growth sub-sector play.
Key Highlights:
- Focus: Veterinary APIs and formulations
- Global reach exports to over 100 countries
- Rising livestock medication demand globally
- Animal health regulations increasing, requiring quality certified products
- Small-cap with global growth potential
Investment Case: India's animal health market is underpenetrated. SeQuent's global scale in a niche segment positions it well as veterinary medicine becomes more regulated worldwide.
4. Alembic Ltd - Diversified Pharma Conglomerate
Alembic Ltd is a diversified entity with pharmaceutical, real estate, and power generation operations. Its pharmaceutical arm emphasises formulations and APIs serving domestic and international markets. Different from the better-known Alembic Pharmaceuticals (separately listed).
Key Highlights:
- Formulations and API manufacturing
- Real estate and power generation provide additional revenue
- Mid-cap company with long operating history
5. Marksans Pharma Ltd - US & UK Generic Specialist
Marksans Pharma focuses on generic formulations for regulated markets including the US, UK, and Australia. It makes OTC and prescription drugs, particularly in pain management and cold/cough segments. It has a track record of USFDA approvals.
Key Highlights:
- Regulated market exposure (US, UK, Australia)
- Strong OTC segment: Paracetamol, ibuprofen, antacids
- Consistent USFDA compliance track record
- Revenue in US dollars natural rupee hedge
Investment Case: Regulated market exposure with OTC stability. A good quality small-cap at an affordable price.
6. Solara Active Pharma Sciences - API Specialist
Solara (part of Strides Group history) is an API-focused company supplying pharmaceutical raw materials to global drug manufacturers. APIs are a critical part of the pharma value chain, and India's China strategy benefits domestic API manufacturers.
Key Highlights:
- API manufacturing for regulated markets
- China procurement shift brings new global customers
- Multiple USFDA approved facilities
7. Suven Pharmaceuticals - CRAMS Leader
Suven Pharmaceuticals operates in the CRAMS (Contract Research And Manufacturing Services) segment, providing services to global innovator drug companies. Long-term CRAMS contracts provide revenue visibility.
Key Highlights:
- Long-term contracts with global pharma innovators
- CNS (Central Nervous System) specialization
- Steady order book visibility
- Demerged from Suven Life Sciences focused business mode
Pharma Stocks Under ₹200: Comparison Table
How to Evaluate Pharma Stocks Under ₹200
Step 1 - Revenue Growth: Look for 15%+ annual revenue growth over 3 years. Flat revenue in pharma indicates lack of new products or market share loss.
Step 2 - EBITDA Margin: Quality pharma companies maintain 20–35% EBITDA margins. Below 15% suggests pricing pressure or high input costs.
Step 3 - USFDA Status: For export-oriented companies, check USFDA facility status. Warning letters or import alerts are red flags.
Step 4 - Debt Levels: Prefer companies with Debt-to-Equity below 1. Over-leveraged pharma companies struggle with R&D investments.
Step 5 - R&D Spend: At least 5–8% of revenue on R&D indicates a company building a future pipeline.
Step 6 - Promoter Holding: High promoter holding (60%+) indicates confidence. Watch for pledged shares as a warning sign.
Step 7 - Regulatory Track Record: Any prior USFDA, WHO, or domestic FDA compliance issues are red flags.
Key Risks in Pharma Stocks Under ₹200
- Regulatory risk: FDA inspections, warning letters, import bans can wipe out export revenue overnight
- Price competition: Generic drugs face rapid price erosion average US generic price falls 20–30% annually
- Patent cliff dependency: If a company is over-dependent on one product, loss of exclusivity hurts hard
- R&D uncertainty: Drug development is long (10+ years) and uncertain. Not all pipeline drugs get approved
- Currency risk: Export revenues in USD/GBP rupee appreciation reduces realisations
- Working capital: Pharma companies need large inventory buffers for APIs and formulations
Biopharma SHAKTI Programme 2026 Tailwind
Budget 2026-27 introduced the Biopharma SHAKTI programme ₹10,000 crore over 5 years to build:
- Biomanufacturing capacity for biosimilars and biologics
- Clinical trial infrastructure
- Research and development ecosystems
This policy push benefits smaller pharma companies by creating demand for domestic biosimilar manufacturing watches for companies in the biologics/biosimilar space under ₹200.
Investment Strategies for Pharma Under ₹200
Strategy 1 - Quality Portfolio (Low Risk): Focus on Marksans (regulated exports) + Morepen (diversified consumer) + Suven (CRAMS). Avoid pure R&D stage companies.
Strategy 2 - Thematic Portfolio (Medium Risk): SeQuent Scientific (animal health) + Solara Active (API / China) + SPARC (innovation).
Strategy 3 - SIP Approach: Given the volatility of small/mid-cap pharma, buy in small quantities every month rather than lump sum. This averages out entry price.
Conclusion
Pharma stocks under ₹200 offer retail investors an affordable gateway into India's world-class pharmaceutical industry. From SeQuent's animal health niche to Marksans' US OTC generics to Morepen's consumer health brands, quality businesses exist at accessible price points.
The key is discipline: focus on companies with USFDA-compliant facilities, growing revenues, low debt, and sustainable business models. Avoid pure penny stocks without fundamentals. The Biopharma SHAKTI programme and India's export push create powerful tailwinds for the sector through 2030.
Open Demat Account and Begin Your Investment Journey!
Open Demat Account and Begin Your Investment Journey!